<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04155554</url>
  </required_header>
  <id_info>
    <org_study_id>2018-004885-32</org_study_id>
    <nct_id>NCT04155554</nct_id>
  </id_info>
  <brief_title>Neurological Monitoring in Patients Switching From Dolutegravir Based Regimen to Bictegravir Based Regimen</brief_title>
  <acronym>DOBINeuro</acronym>
  <official_title>The Effects of Switching From Dolutegravir/Lamivudine/Abacavir (d/l/a) to Bictegravir/Emtricitabine/Tenofovir Alafenamide (b/f/Taf) in Patients With Suppressed Viral Load on Neuropsychiatric Side Effects and Neurocognitive Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliera Universitaria Senese</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Catholic University of the Sacred Heart</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ospedale Policlinico San Martino</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Azienda Ospedaliera San Paolo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ospedale Amedeo di Savoia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Azienda Ospedaliera Universitaria Senese</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, randomized study (1: 1), open-label, controlled, phase 3, multicenter,
      non-profit. The hypothesis of the present study is that bictegravir is associated with a
      lower incidence and severity of neuropsychiatric symptoms than dolutegravir.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective, randomized study (1: 1), open-label, controlled, phase 3, multicenter,
      non-profit. The hypothesis of the present study is that bictegravir is associated with a
      lower incidence and severity of neuropsychiatric symptoms than dolutegravir. The main outcome
      measure will be a global severity index (GSI) of neuropsychiatric symptoms arising from 10
      symptom domains, including somatization, obsessive-compulsiveness, interpersonal sensitivity,
      depression, anxiety, hostility, phobic anxiety, paranoid ideation, psychoticism. The
      secondary outcomes are to compare, between arms and during follow up, neuropsychiatric
      symptoms severity, neurocognitive performance, changes in self-reported symptoms, adherence
      and HR-QoL, correlation between symptoms (neuropsychiatric and other), drug exposure and
      HR-QoL, proportion of adverse events, proportion of virological failures and antiretrovirals
      resistance at virological failure.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 29, 2020</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective, randomized study (1: 1), open-label, controlled, phase 3, multicenter, non-profit</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>neuropsychiatric symptoms severity in 3 months</measure>
    <time_frame>3 months</time_frame>
    <description>change in neuropsychiatric symptoms severity, using the Symptom Checklist-90-R, 3 months after switching to bictegravir or continuing dolutegravir (on treatment analysis).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>neuropsychiatric symptoms severity in 3 and 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>change in neuropsychiatric symptoms severity, each of the 10 symptoms analyzed separately using the Symptom Checklist-90-R, 3 and 12 months after switching to bictegravir or dolutegravir (on treatment analysis)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mini International Neuropsychiatric Interview Plus subscale for suicide risk</measure>
    <time_frame>12 months</time_frame>
    <description>change in neuropsychiatric symptoms severity, using the Mini International Neuropsychiatric Interview Plus subscale for suicide risk, 3 and 12 months after switching to bictegravir or dolutegravir (on treatment analysis). Suicide risk (five questions, score range 0-33 points) in the last 30 days was classified as low (1-5), moderate (6-9), or high (10).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>neurocognitive performance</measure>
    <time_frame>12 months</time_frame>
    <description>change in neurocognitive performance, using a comprehensive and validated neuropsychological battery, 12 months after switching to bictegravir or dolutegravir (on treatment analysis).
The neurocognitive performance is calculated by averaging the individual deficit scores from each neurocognitive test. Deficit scores for each test were calculated from age-, education-, -adjusted raw scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>neurocognitive impairment and neuropsychiatric symptoms</measure>
    <time_frame>12 months</time_frame>
    <description>comparison of the inter-arm and intra-arm incidence of neurocognitive impairment (on the basis of Frascati criteria) at 12 months and neuropsychiatric symptoms (using the Symptom Checklist-90-R) at 3 (on treatment analysis) and 12 months (ITT-exposed, using LOCF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>self-reported symptoms (21 items, 0-5 points for each), adherence (0-100%) and HR-QoL (9 items, 0-5 points for each)</measure>
    <time_frame>12 months</time_frame>
    <description>changes in self-reported symptoms, adherence and HR-QoL (using validated questionnaires) during the first year of follow up (ITT-exposed, using LOCF).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>drug exposure</measure>
    <time_frame>12 months</time_frame>
    <description>correlation between symptoms (neuropsychiatric and other), drug exposure and HR-QoL during the first year of follow up (ITT-exposed, using LOCF).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>12 months</time_frame>
    <description>proportion of adverse events and serious adverse events and of patients discontinuing due to side effects in both arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>virological failures</measure>
    <time_frame>12 months</time_frame>
    <description>proportion of virological failures and antiretrovirals resistance at virological failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Satisfaction</measure>
    <time_frame>12 months</time_frame>
    <description>change in Treatment Satisfaction between arms as per specific questionnaire (TSQM Version 1.4, 15 questions, from 0 to 79 points as maximum)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>HIV-1-infection</condition>
  <arm_group>
    <arm_group_label>Bictegravir/emtricitabine/tenofovir alafenamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with suppressed viral load switching from dolutegravur/lamivudina/abacavir (50/300/600 mg) 1 tablet OD to bictegravir/emtricitabine/tenofovir alafenamide (50/200/25 mg) 1 tablet OD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dolutegravir/lamivudine/abacavir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with suppressed viral load continuing dolutegravir/lamivudine/abacavir (50/300/600 mg) 1 tablet OD</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bictegravir/emtricitabine/tenofovir alafenamide</intervention_name>
    <description>Switch patients from dolutegravir/lamivudine/abacavir to bictegravir/emtricitabine/tenefovir alafenamide to study neuropsychiatric side effects and neurocognitive function</description>
    <arm_group_label>Bictegravir/emtricitabine/tenofovir alafenamide</arm_group_label>
    <other_name>Biktarvy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dolutegravir/lamivudine/abacavir</intervention_name>
    <description>Continuing dolutegravir/lamivudine/abacavir to study neuropsychiatric side effects and neurocognitive function</description>
    <arm_group_label>Dolutegravir/lamivudine/abacavir</arm_group_label>
    <other_name>Triumeq</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;18 years

          -  HIV-1 infection

          -  HIV RNA &lt;50 copies/mL &gt;12 months (including patients with 1 blip 50-200 cp/mL before
             screening, not confirmed)

          -  On treatment with dolutegravir/abacavir/lamivudine &gt;6 months

        Exclusion Criteria:

          -  Previous AIDS events

          -  Pregnancy or pregnancy plan

          -  Decompensated cirrhosis (B or C CPT status)

          -  Intake of alcohol, substances, other drugs that may affect neurocognitive performances

          -  Necessity to receive drugs that may require dosing adjustment of dolutegravir or
             bictegravir

          -  Certified diagnosis of major depression, psychosis, history of suicidal attempts

          -  Treatment with antidepressants or antipsychotic drugs

          -  History of virological failure with INSTIs

          -  Lack of knowledge of italian language

          -  Impossibility to obtain informed written consent

          -  HBsAg positivity

          -  Estimated glomerular filtration rate by CK-EPI &lt;50 mL/min per 1.73 m2
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barbara Rossetti, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Azienda Ospedaliera Universitaria Senese</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Barbara Rossetti, PhD</last_name>
    <phone>+393201437658</phone>
    <email>barbara.rossetti@ao-siena.toscana.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maurizio Zazzi, Prof</last_name>
    <phone>+390577233863</phone>
    <email>maurizio.zazzi@unisi.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Barbara Rossetti</name>
      <address>
        <city>Siena</city>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara Rossetti, PhD</last_name>
      <phone>+393201437658</phone>
      <email>barbara.rossetti@ao-siena.toscana.it</email>
    </contact>
    <contact_backup>
      <last_name>Maurizio Zazzi, Prof</last_name>
      <phone>+390577233863</phone>
      <email>maurizio.zazzi@unisi.it</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>November 5, 2019</study_first_submitted>
  <study_first_submitted_qc>November 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 7, 2019</study_first_posted>
  <last_update_submitted>January 29, 2020</last_update_submitted>
  <last_update_submitted_qc>January 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Ospedaliera Universitaria Senese</investigator_affiliation>
    <investigator_full_name>Barbara Rossetti</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Neurocognitive functions</keyword>
  <keyword>Neuropsychiatric side effects</keyword>
  <keyword>Bictegravir</keyword>
  <keyword>INSTI</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Abacavir</mesh_term>
    <mesh_term>Dolutegravir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

